AstraZeneca PLC
Change company Symbol lookup
Select an option...
AZN AstraZeneca PLC
CLZNY Clariant AG
CARR Carrier Global Corp
SMIT Schmitt Industries Inc
OOMA Ooma Inc
SEDG Solaredge Technologies Inc
CELH Celsius Holdings Inc
BABA Alibaba Group Holding Ltd
CS Credit Suisse Group AG

Health Care : Pharmaceuticals | Large Cap Growth
Based in United Kingdom
Company profile

AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Closing Price
Day's Change
0.01 (0.02%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

AMD's stock price target raised at Susquehanna, a day before the earnings report

6:50 am ET October 26, 2020 (MarketWatch)

Advanced Micro Devices Inc.'s (AMD) stock price target was raised Monday to $95 from $85 by Susquehanna analyst Christopher Rolland, who cited expectations that the chip maker will beat expectations, when it reports third-quarter results after Tuesday's close. The stock slipped 0.3% in premarket trading, while futures for the S&P 500 dropped 0.9%. Rolland reiterated the positive rating he's had on AMD since July. He said that while Wall Street expectations provide a "challenging bar" for AMD to clear, "we believe the next-gen gaming console ramp and continued strength in the PC market should be enough for AMD to clear it," Rolland wrote in a note to clients. The FactSet consensus is for earnings of 35 cents a share on revenue of $2.56 billion. Rolland said his research suggests AMD continues to gain market share in both desktops and laptops. Rolland said the set up for the stock is "favorable" ahead of the earnings report, especially given how it has underperformed the sector since the second-quarter report. The stock has rallied 78.7% year to date through Friday, while the PHLX Semiconductor Index has advanced 27.6% and the S&P 500 has gained 7.3%.

-Tomi Kilgore; 415-439-6400;

(END) Dow Jones Newswires

October 26, 2020 06:50 ET (10:50 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.